Aerie Pharmaceuticals — Investor Presentation (August 2021)
34 slides from Aerie Pharmaceuticals's investor presentation, Aug 11, 2021
Slide 1: Company Overview Investor Presentation August 2021
Company Overview Investor Presentation August 2021 Exhibit 99.1
Slide 2: Important Information
For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified
Slide 3: Aerie Overview
Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA and EMA. AR-15512, AR-1105, AR-13503, AR-14034 and AR-6121 are development stage product candidates and are not approved by any regulatory agency. Dex: Dexamethasone Aerie IOP–Reducing Prod
Slide 4: Aerie Overview: U.S. Glaucoma Market
Aerie Overview For Investor Use Sources: IQVIA: NPA Rx and NSP Unit data Estimated Aerie TRx Mix Medicare Part D & Medicaid, 62% Commercial & Cash, 24% Graph Source: IQVIA 2020 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker - ~$3B Market, 34M TRx, 55M bottles - 55% of unit volu
Slide 5: Glaucoma Commercialization Focus
Glaucoma Commercialization Focus Ongoing communication of the MOST Data and coverage via various communication channels Rhopressa® Coverage: 77% Commercial, 92% Med D Rocklatan® Coverage: 75% Commercial, 74% Med D plus 10% Low Income Subsidy Continued execution of the Pulse Strategy, focused on driv
Slide 6: Focused on Pull-Through to Gain Share
Focused on “Pull-Through” to Gain Share: Example from 05/01/20 Med D Coverage Win Franchise Market Share April 2020¹ June 2021 Part D National Market Share 1.85% 2.35% New Payer Part D Market Share 0.98% 2.13% Market Share Difference (“Gap”) -0.87% -0.22% ¹ April 2020 was the last month our Brands w
Slide 7: U.S. Glaucoma Franchise Update
For Investor Use U.S. Glaucoma Franchise Update Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA and EMA. Actual Weekly Sales-Out to Pharmacies Data as of 8/6/2021 IQVIA Weekly Data as of 7/30/2021 IQVIA reporting for all reported industry products chan
Slide 8: Aerie Franchise vs Key Brand Competitors
Aerie Franchise vs Key Brand Competitors Product Jun ‘21 vs. Jun ‘20 TRx Gain / (Loss) Aerie (Rhopressa® & Rocklatan® ) 23% 10,982 Vyzulta® 35% 5,214 Simbrinza® -14% -4,959 Azopt® -60% -21,502 Alphagan® P -6% -4,270 Combigan® -5% -6,853 Lumigan® -4% -7,914 Glaucoma Market 2% 71,084 Aerie franchise c
Slide 9: Advancing the Pipeline
For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b AR-15512 (TRPM8 agonist) Dry Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 SR Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement AR-14034 SR Implant (VEGF-A/B/C/D) wAMD/DM
Slide 10: U.S. Dry Eye Market: Under-diagnosed and Under-treated
For Investor Use U.S. Dry Eye Market: Under-diagnosed and Under-treated Estimated 30 million dry eye sufferers in the United States; less than 3 million treated Dry eye related symptoms are one of the most common reasons for patients to visit an eye care professional Represents a significant health
Slide 11: AR-15512 for Dry Eye: Novel Mechanism of Action
AR-15512 for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors Topical eye drop TRPM8 receptor is a cold thermoreceptor ion channel located on corneal nerve endings Reduced corneal temperature triggered by tear evaporation activates TRPM8 which leads to: Increased basal tear
Slide 12: AR-15512 (TRPM8 Agonist) for Dry Eye: How It Works
AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution
Slide 13: AR-15512 for Dry Eye: Phase 2a Study
AR-15512 for Dry Eye Avizorex completed a Phase 2a study in early 2019 in 109 subjects One concentration (0.0014%) and two dosing regimens (BID/TID) for 4 weeks were evaluated Primary endpoint: % of patients ≥ 20 points change in symptoms questionnaire (SANDE) Secondary endpoints: Schirmer’s test (t
Slide 14: Significant efficacy for sign and symptoms with BID dosing
Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days For Investor Use * = statistical significance ++Data on File AR-15512 is a development stage product candidate and is not approved by any regulatory agency. . Symptoms: SANDE Score P
Slide 15: AVX-012 Dry Eye Clinical Trial Highlights: Schirmer
* = statistical significance ++Data on File AR-15512 is a development stage product candidate and is not approved by any regulatory agency. For Investor Use AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Significant efficacy achie
Slide 16: Dry Eye Program: AR-15512
For Investor Use Dry Eye Program: AR-15512 Target symptoms: significant step in addressing the symptoms of dry eye patients and providing a cooling sensation Impact basal tear production: production of natural tears and not just an acute reflex tear Safe for long-term use Other approved products on
Slide 17: AR-15512: COMET-1 Phase 2b Underway
For Investor Use AR-15512: COMET-1 Phase 2b Underway Clinical Trial Series named “COMET” = Cold Thermoreceptor Modulation as an Effective Treatment Phase 2b clinical study commenced October 2020; enrollment completed April 2021 Phase 2b study is evaluating efficacy and safety of 0.0014% and 0.003% B
Slide 18: 2019 U.S. Retinal Disease Market
For Investor Use 2019 U.S. Retinal Disease Market: Need for Reduced Injection Frequency, New MOAs Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 Frequent intravitreal injections required to maintain vision gains Represents a significant burden for patients and p
Slide 19: Proprietary Drug Delivery Platform for Retinal Disease
For Investor Use Aerie’s Proprietary Drug Delivery Platform for Retinal Disease – Predictable and Flexible Customizable drug elution, reproducible manufacturing Proprietary bio-erodible formulations, PRINT ® manufacturing Longer treatment duration, reduced injection frequency Enables once or twice p
Slide 20: Proprietary Drug Delivery Technology: Platform for Future Innovation
For Investor Use Aerie’s Proprietary Drug Delivery Technology: A Platform for Future Innovation Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg wAMD DME RVO Dry AMD/GA Glaucoma Othe
Slide 21: AR-1105 (Dexamethasone) Implant
AR-1105 (Dexamethasone) Implant Positive Topline Phase 2 results in RVO Phase 3 plans underway for the U.S. and Europe for DME Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administration due to smaller needle Potential for fewer ad
Slide 22: AR-1105 Implant: Phase 2 Topline Summary
AR-1105 (Dexamethasone) Implant: Phase 2 Topline Summary The Phase 2 clinical trial (AR-1105-CS201) was conducted at 19 centers in the United States The objective was to evaluate two clinical formulations of AR-1105, CF-1 and CF-2 (each containing 340 µg dexamethasone), with different release profil
Slide 23: AR-1105 Opportunity
AR-1105 Opportunity The DME market is growing in the United States and abroad The 6-month sustained efficacy of AR-1105 in the P2 study may render this product, if approved, highly competitive in both the U.S. and European markets AR-1105 may be viewed as a more favorable treatment alternative for a
Slide 24: AR-14034 SR (Axitinib) Implant Opportunity
AR-14034 SR (Axitinib) Implant Opportunity 1. Market Scope Estimates 2020; http://market-scope.com/ Aflibercept Ranibizumab Bevacizumab Brolucizumab Axitinib For Investor Use 2019 IVT anti-VEGF worldwide market $13B; est. $22B by 20251 Current anti-VEGF pipeline dominated by longer duration products
Slide 25: Axitinib Is Preferred Small Molecule for VEGF Inhibition
Axitinib Is Preferred Small Molecule for VEGF Inhibition Pan-VEGF receptor inhibitor (inhibits all isoforms of VEGF-R) Approved for systemic use in 2012 for the treatment of renal cell carcinoma Higher potency and less off-target activity than other small molecule inhibitors Most selective For Inves
Slide 26: Axitinib Implant: Results Support Up to 12 Months Duration
Axitinib Implant: Results Support Up to 12 Months Duration in Clinic Proprietary polymer blend produces optimal drug elution profile Maintains high elution rate over time Drug release rate in rabbits predicts up to 12-months duration (once a year injection) in clinic Aerie rabbit data accurately pre
Slide 27: Ophthalmic Steroid Market Opportunity
Ophthalmic Steroid Market Opportunity There are approximately 11 million steroid TRx units in the US market1 Potency and corneal penetration are key attributes of any topical steroid Strong steroids represent 80% of the marketplace lead by prednisolone Loteprednol is the leading soft steroid All ste
Slide 28: Concept and Chemistry: ROCK'Sters
For Investor Use Concept and Chemistry: ROCK’Sters ROCK inhibitor-Linked Steroid ROCK’Sters are a proprietary class of potent ocular corticosteroids linked to ROCK inhibitors (ROCKi) Rationale for design: to leverage the anti-fibrotic and IOP-lowering activities of ROCK inhibitors to generate potent
Slide 29: In Vivo Efficacy: Mouse Endotoxin-Induced Uveitis Model
For Investor Use In Vivo Efficacy: Mouse Endotoxin-Induced Uveitis Model (24 hrs.) AR-6121 compared to 0.05% Durezol® AR-6121 is at least as effective as Durezol® in the mouse EIU model EIU has been used to model human anterior uveitis: to investigate the dynamics of resolving inflammation (e.g., le
Slide 30: Expanding Aerie Franchise: Japan
For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful topline results released in November 2019 First Phase 3 trial in Japan fully enrolled; Topline results expected in Q4 2021 Sources: IMS Analytics link at ex-manufacturer price level and Unit-April 2021. *TRx calculated from I
Slide 31: Japan Phase 2 Study Topline Results
AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim
Slide 32: Japan Phase 2 Study Topline Results: IOP vs placebo
P<0.0001 vs. placebo at Week 4 for all dose levels1 0.02% achieved lowest mean diurnal IOP at Week 4 1. ANCOVA with MCMC imputation AR-13324-CS208 Japan Phase 2 Study Topline Results For Investor Use
Slide 33: Expanding Aerie Franchise: Europe
For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019 and for Roclanda® (Rocklatan®) in January 2021 Mercury 3: Reported successful 90-day topline data in September 2020; Rocklatan® (known as Roclanda® in Europe) achieved non-
Slide 34: Summary Key Priorities
For Investor Use Summary Key Priorities Driving continued Rhopressa® and Rocklatan® volume growth in the U.S. Globalization Strategy Japan: Santen collaboration commencing and first Phase 3 trial underway Europe: Significant interest from potential collaborators Ireland Manufacturing Facility approv
Aerie Pharmaceuticals — Investor Presentation (August 2021) on 6ix